General Information

We are a clinical-stage biopharmaceutical company focused on applying our novel Hierotope platform to identify unique disease targets and to design and engineer innovative antibody-based therapies that are intended to be effective as a single-dose administration. We believe that our platform enables us to address the significant unmet need for effective therapies to treat infectious diseases caused by organisms that have a high degree of diversity among strains, frequent mutations and a high prevalence of treatment resistance. Our most advanced product candidate, VIS410, is a monoclonal antibody, or mAb, that we are developing for the treatment of hospitalized patients with influenza A, regardless of the viral strain.

Employees: 42
Founded: 2007
Contact Information
Address One Kendall Square, Suite B3301, Cambridge, MA 02139, US
Phone Number (617) 498-1070
Web Address
View Prospectus: Visterra
Financial Information
Market Cap $211.8mil
Revenues $15.4 mil (last 12 months)
Net Income $-20.7 mil (last 12 months)
IPO Profile
Symbol VIST
Exchange NASDAQ
Shares (millions): 3.9
Price range $12.00 - $14.00
Est. $ Volume $50.1 mil
Manager / Joint Managers Leerink Partners/ Stifel
CO-Managers Needham & Company/ Wedbus/ PacGrow
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change